This doctor has a system

Chapter 553 616. How dare you question it

Looking at that handsome face, Jiang Yuanlintaro was full of jealousy. You can obviously make a living with your face, why do you have to rely on your own ability? What should we do?
He is about the same height as Gao Feng, but his facial features are very different.

Rintaro Ehara's cheekbones are too broad and can be seen from behind his ears. According to the Chinese, this is called "cheeks visible behind the ears". People with this feature are mostly heartless and ungrateful. They are narrow-minded, cunning, and ruthless.

His face is even more unpleasant, with a typical wolf-like and tiger-like appearance.

The so-called "wolf walk" refers to the situation where when a person looks back while walking, only the head turns while the body does not move. The so-called "tiger kiss" refers to the habit of gritting teeth at any time, smiling from a distance but looking angry up close, or sometimes suddenly sneering and speaking hypocritically and insincerely.

People with the appearance of wolf-like steps and tiger-like kisses are scheming and sinister. They are cunning, do not do things in an upright manner, and like to scheme against others.

When he was a child, Rintaro Ehara suffered a lot because of his facial features.

But there is no way, this is given by our parents, and the only way to change it is through plastic surgery.

Gao Feng keenly noticed the hostile look, and Li Youliang on the side immediately revealed the other party's identity.

It's normal to be hostile. He and the other teacher are rivals. If Rintaro Ehara showed affection towards him, he would think it was abnormal.

The Nobel Prize is intended to honor people who have made the "greatest contribution to humanity" in physics, chemistry, physiology or medicine, and literature.

What does this mean?
Obviously, whoever obtains this will be the person who has made the greatest contribution to mankind. Not only will he gain great glory, but his disciples will also benefit from it.

No one dares to look down on the disciples of academicians, but what about the disciples of Nobel Prize winners?
Rintaro Ehara knows his own limitations and knows that he will never be able to win such an award in his lifetime. His greatest scientific research resource is his teacher.

The more the teacher is arrogant, the more arrogant he is. The teacher is a idiot, and he eats grass.

Naturally, he didn't want to eat grass. He wanted to eat meat, and he wanted to eat his fill.

Therefore, now people are eager to become successful teachers.

Otherwise, if he has no grudge against Gao Feng, why would he be so hostile to him?

Gao Feng didn't care about this little island with a less-than-ideal appearance. His opponent was the other party's teacher, and such an ant-level person was not even worth his attention.

The exchange meeting was not formal, it was just a routine monthly program of the Karolinska Institute, but quite a few people came today.

"It is said that Professor Gao Feng from China will also be attending." A student was talking to his classmates, "He knows Kung Fu!"

"He must also be a fitness expert, otherwise he wouldn't have been able to subdue three gangsters." A muscular man interrupted, "I'm very interested in him!"

"Shut up, fag!" someone yelled. "Go back to your gym!"

The people in front of them moved quickly because they knew they were not the protagonists today. Soon, Gao Feng walked onto the podium.

"Hello everyone." He greeted.

"He's a gigolo!"

"He has a very charming smile. I'm imagining his face against my chest," said a girl.

The person next to her looked at her two towering peaks and his heart suddenly moved.

"You'll probably suffocate Professor Huaguo to death if you do this." "Why not let me do it!"

"Are you worthy? You look like a stick!" the girl said disdainfully.

"Marilyn, I always thought you weren't the type of girl who judges people by appearance."

"You're blind! Let me tell you, I only sleep with handsome guys!"

Gao Feng shared his views on targeted therapy for lung adenocarcinoma, which was also the theme of this exchange meeting.

"The development of third-generation TKI drugs has greatly extended the survival of patients with gene mutations, but it should be noted that some patients quickly develop drug resistance after taking these drugs."

According to the original intention when the drug was developed, the third-generation TKI drugs are used for adult patients with locally advanced or metastatic non-small cell lung cancer who have experienced disease progression during or after treatment with epidermal growth factor receptor tyrosine kinase inhibitors and who have been confirmed to have EGFR T790M mutation-positive.

But in clinical practice, this drug is often used for initial treatment.

This is not abuse by doctors, but the first and second generation tyrosine kinase inhibitors are very ineffective and have many side effects for patients with systemic metastases, especially brain metastases.

The third-generation drugs can pass through the blood-brain barrier and have few side effects, which is why many doctors favor them.

Gao Feng's research on targeted treatment of lung adenocarcinoma is obviously beyond the reach of these medical students in the ivory tower. He just talked about it a little more deeply, and many people were at a loss.

"Does anyone want to ask questions?" the host asked.

Rintaro Ehara stood up immediately.

A smile immediately appeared on Gao Feng's face. Something was going to happen on this little island. He was so looking forward to it!
"Professor Gao, I would like to ask what you think about the treatment of G719X mutation?"

As soon as this question was raised, Professor Norman's face looked a little unhappy. It was obvious that this little island was here to cause trouble.

There are many types of EGFR mutations, among which exon 19 deletion (del19) and L858R point mutation account for about 85% of all mutations.

In addition, there are about 15% of rare EGFR mutations. These rare mutations are highly heterogeneous and have a low incidence, so there is still a lack of high-quality treatment evidence.

The G719X mutation is one of them, accounting for about 3% of the total.

Compared with classic mutations, G719X often presents as a compound mutation, which is insensitive to the first-generation EGFR TKI. For example, the median PFS of gefitinib is only 6.3-8.1 months.

"I suggest that these patients try second-generation TKI, such as afatinib," Gao Feng said to the crowd, "It is better than the third-generation drugs."

"That's nonsense!" Jiang Yuanlintaro was a little impatient, "How can the third-generation TKI be weaker than the second-generation?! Their effects are more widely distributed in the body and can pass through the blood-brain barrier."

He stood there and blared for a long time like a little loudspeaker.

This ugly man caused dissatisfaction among many people. His aggressiveness was quite strong, which formed a sharp contrast with Gao Feng who had a smile on his face.

"Da Lang." Gao Feng interrupted him. "I'm Taro!" Jiang Yuanlintaro was very dissatisfied. Don't think he didn't know Wu Dalang's story. "Please call me Jiang Yuanlintaro!"

"Okay, Mr. Jiang Yuanlintaro." Gao Feng followed suit, "I don't agree with your remarks."

"Professor Terry Kent of New York Medical College and I conducted a clinical trial on 150 patients with G719X mutations. Although the final conclusion has not yet come out, we have found that the vast majority of patients treated with afatinib have a faster improvement in their condition, and"

"Some of the relevant papers have been published in the New England Journal of Medicine. You can take a look at it if you have time."

Baka! Jiang Yuanlintaro cursed in his heart.

His questions were obviously very tricky, but the Chinese man was so lucky that it seemed as if he was the one who took the initiative to step forward and be slapped in the face.

Absolutely abominable!
"Although he is not convinced, Rintaro Ehara's face is swollen after being slapped by you. You have gained 3 skill points." The system prompts.

Oh!

"Mr. Rintaro Ehara, do you have any other questions?" Gao Feng was very enthusiastic. He could easily defeat this kind of scumbag with any high-level questions.

You are my experience pack.

Rintaro Jiang Yuan was stunned for a moment. He didn't expect Gao Feng would actually ask him to ask questions on his own initiative. At the same time, he was even more angry.

He felt that the question he had just asked was a lucky coincidence. If he had asked a more tricky and unusual question, he would have been able to stump this pretty boy.

"What question should I ask?" Jiang Yuanlin hesitated. The theme of today's exchange meeting was targeted therapy for lung adenocarcinoma. He couldn't rashly raise other irrelevant questions. Otherwise, even if Gao Feng couldn't answer them, it wouldn't damage his reputation.

After thinking for a few seconds, Rintaro Ehara's eyes lit up, and he actually thought of a point of entry.

"Professor Gao, you are an expert in targeted therapy for lung adenocarcinoma. What do you think of Rexedinib, a drug recently developed by our island country?"

"According to clinical trials, its effect on patients with EGFR exon 20 insertion mutation is better than that of the third-generation TKI!"

“I know you also led the development of a targeted drug, but rexitinib has received accelerated approval from the FDA, and it may even be available earlier.”

"Do you think this situation has something to do with the backwardness of China's pharmaceutical industry?"

Baka! Gao Feng was a little angry. This little bastard was really good at disgusting him.

He immediately entered the system space to check the drug called Rexitinib. Now all major companies are rushing on the road of targeted therapy, and there are many drugs under development that even Gao Feng is not familiar with.

Non-small cell carcinoma is the most common type of lung cancer, in which EGFR mutation occurs in about 40% of cases, making it the most common and most mature gene mutation.

In addition to common EGFR mutations (19DEL, L858R), EGFR exon 20 mutations account for approximately 12% of EGFR mutations, making it the third largest type of EGFR mutation. Compared with other common EGFR mutations, it is more malignant and has limited benefits from traditional chemotherapy.

Rexitinib is a drug developed by Japan's Takeda Pharmaceutical specifically for patients with this mutation and is currently in the clinical trial stage.

The FDA granted accelerated approval to rexitinib for adult patients with locally advanced or metastatic non-small cell carcinoma harboring EGFR exon 20 whose disease has progressed on or after prior platinum-containing chemotherapy.

Soon, a smile appeared on Gao Feng's face because he saw the two articles.

The first article pointed out that the efficacy of ricksetinib alone in the first-line treatment of advanced non-small cell carcinoma with EGFR exon 20 was not ideal, which directly denied its validity as a single-agent second-line treatment.

The second article made Gao Feng even happier. This paper, which will be published in the journal Nature Medicine in the future, pointed out that some elderly patients who used rexitinib had obvious cardiac toxicity, including possible QTc interval prolongation and torsade de pointes ventricular tachycardia.
The reason for this side effect is that there are four methyl groups in the molecular structure of rexitinib, one of which cannot be completely converted after entering the body. After being metabolized and decomposed in the body, it will produce an oxidase that competitively binds to the coupled receptors on the cardiomyocytes, thereby causing myocardial damage.

This situation will be discovered two years after the drug is on the market, but by that time it has already caused harm to many patients.

Later, the International Association for the Treatment of Lung Cancer removed this drug from the treatment guidelines for EGFR exon 20 mutations, and Takeda Pharmaceutical was severely damaged as a result.

Of course, this is a matter for the future. Currently, this drug is still in the clinical trial stage.

"Da Lang is one of us!" Gao Feng praised Jiang Yuanlintaro in his heart. The other party was afraid that he was not famous enough, so he came to give him a big gift package!

"I've heard a little bit about this drug." He organized his words, "But I think it has major flaws, and the current clinical trials don't meet the requirements."

What? Jiang Yuanlintaro suspected that there was something wrong with his ears, and his reaction was unbelievable anger.

Damn Chinese! How dare he say such outrageous things!
"Arrogant!" Jiang Yuanlintaro shouted, "Who do you think you are?! Rexitinib is a blockbuster product developed by Takeda Pharmaceuticals in collaboration with multiple international institutions. Even the FDA has given it accelerated approval."

"How dare you question it!"

They also say that there are huge defects, which is simply like buying salted fish and letting it go - they don't know how to live or die!
Professor Norman on the side frowned and began to worry about Gao Feng.

Takeda Pharmaceutical is not an unknown company. Founded in 1781 and headquartered in the island nation, it is a global leading biopharmaceutical company with branches in 80 countries and regions around the world and approximately 50 employees.

As the saying goes, cutting off someone's financial resources is like killing their parents. For a profit-seeking pharmaceutical company like this, a new drug that is about to pass clinical trials means staggering wealth.

Takeda Pharmaceutical must have high hopes for it and would not tolerate others questioning it in the final clinical trial stage, even if the problems are real.

If Gao Feng could produce evidence, then everything would be fine. But if he had nothing to prove, he would have to face the other party's crazy counterattack.

Professor Norman is well aware of the moral practices of these pharmaceutical companies and feels very uneasy.

"Still too young." He thought as he looked at Gao Feng's energetic face.

"Gao Feng! You will pay the price for your arrogant remarks today!" Rintaro Jiang Yuan's heart was filled with joy at this moment. He had already realized that it was a little ridiculous that he was so angry just now.

Isn't the purpose of coming here today to find out some mistakes of the other party? !

Now, as soon as the news gets out, he won’t have to do anything, Takeda Pharmaceutical will pounce on this pretty boy and bite him to pieces.

Even if the other party can get away with it unscathed, he will most likely lose the opportunity to compete with his teacher for the Nobel Prize in Medicine next year.

As for the possibility that Gao Feng really has evidence that rexitinib has substantial defects, please, the drug is not yet on the market, where does he get the evidence?
Some insignificant news revealed by Takeda Pharmaceutical?

Simply ridiculous!
(End of this chapter)